<DOC>
	<DOC>NCT00619476</DOC>
	<brief_summary>The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with post-herpetic neuralgia (PHN).</brief_summary>
	<brief_title>A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)</brief_title>
	<detailed_description>The primary purpose of study PXN110748 was to evaluate efficacy and safety of 3 fixed doses of GEn in the treatment of PHN.</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia, Postherpetic</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>18 years or older Female subjects are eligible if of nonchildbearing potential or not lactating, has a negative pregnancy, and agrees to use one a specified highly effective method for avoiding pregnancy Documented medical diagnosis of PHN of with pain present for at least three months from the healing of a herpes zoster rash Baseline 24hour average pain intensity score ≥ 4.0 based on an 11point PINRS Provides written informed consent in accordance with all applicable regulatory requirements Other chronic pain conditions not associated with PHN. However, the subject will not be excluded if: The pain is located at a different region of the body; and The pain intensity is not greater than the pain intensity of the PHN; and The subject can assess PHN pain independently of other pain Is unable to discontinue prohibited medications or nondrug therapies or procedures throughout the duration of the study Hepatic impairment defined as ALT or AST &gt; 2x upper limit of normal (ULN), or alkaline phosphatase or bilirubin &gt; 1.5x ULN Chronic hepatitis B or C Impaired renal function defined as creatinine clearance &lt;60 mL/min or requiring hemodialysis Corrected QT (QTc) interval ≥ 450 msec or QTc interval ≥480 msec for patients with Bundle Branch Block Uncontrolled hypertension at screen (sitting systolic &gt;160 mmHg and/or sitting diastolic &gt;90 mmHg) Current diagnosis of active epilepsy or any active seizure disorder requiring chronic therapy with antiepileptic drugs Medical condition or disorder that would interfere with the action, absorption, distribution, metabolism, or excretion of GEn, or, in the investigator's judgment Is considered to be clinically significant and may pose a safety concern, or, Could interfere with the accurate assessment of safety or efficacy, or, Could potentially affect a subject's safety or study outcome Meets criteria defined by the DSMIVTR for a major depressive episode or for active significant psychiatric disorders within last year Depression in remission, with or without antidepressant treatment, may participate, unless stable antidepressant regimen is a prohibited medication Antidepressant medication may not be changed or discontinued to meet entry criteria and must be stable for at least three months prior to enrollment History of clinically significant drug or alcohol abuse (DSM‑IV‑TR) or is unable to refrain from substance abuse throughout the study. Benzodiazepines or atypical benzodiazepines as hypnotic sleep agents permitted. Currently participating in another clinical study in which the subject is, or will be exposed to an investigational or noninvestigational drug or device Has participated in a clinical study and was exposed to investigational or non‑investigational drug or device: Within preceding month for studies unrelated to PHN, or Within preceding six months for studies related to PHN Treated previously with GEn History of allergic or medically significant adverse reaction to investigational products (including gabapentin) or their excipients, acetaminophen or related compounds</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Neuropathic Pain</keyword>
	<keyword>Post-herpetic neuralgia</keyword>
	<keyword>PHN</keyword>
</DOC>